|
1
|
Myles ZM, Buchanan N, King JB, Singh S,
White A, Wu M and Ajani U: Anatomic distribution of malignant
melanoma on the non-Hispanic black patient, 1998–2007. Arch
Dermatol. 148:797–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
NIH National Cancer Institute:
Surveillance, Epidemiology, and End Results Program, Cancer Stat
Facts: Melanoma of the Skin (EB/OL). https://seer.cancer.gov/statfacts/html/melanhtml2017
|
|
3
|
Golabchi K, Soleimani-Jelodar R, Aghadoost
N, Momeni F, Moridikia A, Nahand JS, Masoudifar A, Razmjoo H and
Mirzaei H: MicroRNAs in retinoblastoma: Potential diagnostic and
therapeutic biomarkers. J Cell Physiol. 233:3016–3023. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gholamin S, Mirzaei H, Razavi SM,
Hassanian SM, Saadatpour L, Masoudifar A, ShahidSales S and Avan A:
GD2-targeted immunotherapy and potential value of circulating
microRNAs in neuroblastoma. J Cell Physiol. 233:866–879. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang J, Lu L, Xiong Y, Qin W, Zhang Y,
Qian Y, Jiang H and Liu W: MLK3 promotes melanoma proliferation and
invasion and is a target of microRNA-125b. Clin Exp Dermatol.
39:376–384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang J, Na S, Liu C, Pan S, Cai J and Qiu
J: MicroRNA-125b suppresses the epithelial-mesenchymal transition
and cell invasion by targeting ITGA9 in melanoma. Tumour Biol.
37:5941–5949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Wang L, Briggs C, Sicinska E,
Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, et al:
DNA degradation test predicts success in whole-genome amplification
from diverse clinical samples. J Mol Diagn. 9:441–451. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
von Ahlfen S, Missel A, Bendrat K and
Schlumpberger M: Determinants of RNA quality from FFPE samples.
PLoS One. 2:e12612007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, HessK R,
Sullivan DC, et al: AJCC cancer staging manual. 8th. Springer; New
York, NY: 2017, View Article : Google Scholar
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu S and Singh RK: Resistance to
chemotherapy and molecularly targeted therapies: Rationale for
combination therapy in malignant melanoma. Curr Mol Med.
11:553–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garbe C, Peris K, Hauschild A, Saiag P,
Middleton M, Bastholt L, Grob JJ, Malvehy J, Newton-Bishop J,
Stratigos AJ, et al: Diagnosis and treatment of melanoma. European
consensus-based interdisciplinary guideline-update 2016. Eur J
Cancer. 63:201–217. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fredsøe J, Rasmussen AKI, Thomsen AR,
Mouritzen P, Høyer S, Borre M, Ørntoft TF and Sørensen KD:
Diagnostic and prognostic MicroRNA biomarkers for prostate cancer
in cell-free urine. Eur Urol Focus. 4:825–833. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang SM and Hu WW: Long non-coding RNA
MALAT1 promotes oral squamous cell carcinoma development via
microRNA-125b/STAT3 axis. J Cell Physiol. 233:3384–3396. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang L, Zhang X, Ma Y, Zhao X, Li B and
Wang H: Ascites promotes cell migration through the repression of
miR-125b in ovarian cancer. Oncotarget. 8:51008–51015.
2017.PubMed/NCBI
|
|
16
|
Kappelmann M, Kuphal S, Meister G,
Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma
progression by direct regulation of c-Jun protein expression.
Oncogene. 32:2984–2991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Glud M, Rossing M, Hother C, Holst L,
Hastrup N, Nielsen FC, Gniadecki R and Drzewiecki KT:
Downregulation of miR-125b in metastatic cutaneous malignant
melanoma. Melanoma Res. 20:479–484. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma H, Bandos AI and Gur D: On the use of
partial area under the ROC curve for comparison of two diagnostic
tests. Biom J. 57:304–320. 2015. View Article : Google Scholar : PubMed/NCBI
|
